SLC5A2 and chronic kidney disease: In fact, in vitro studies have found that SGLT2 inhibition prevents EMT-phenotypes changes in tubular cells by the suppression of sirtuin 3 and aberrant glycolysis [73], suggesting that targeting damage in this cell type could be a good therapeutic option for CKD.